Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial
BACKGROUND: the addition of oligosaccharides to infant formula has been shown to mimic some of the beneficial effects of human milk. The aim of the study was to assess the tolerance and safety of a formula containing an innovative mixture of oligosaccharides in early infancy. METHODOLOGY/PRINCIPAL F...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227609/ https://www.ncbi.nlm.nih.gov/pubmed/22140499 http://dx.doi.org/10.1371/journal.pone.0028010 |
_version_ | 1782217766842925056 |
---|---|
author | Piemontese, Pasqua Giannì, Maria L. Braegger, Christian P. Chirico, Gaetano Grüber, Christoph Riedler, Josef Arslanoglu, Sertac van Stuijvenberg, Margriet Boehm, Günther Jelinek, Jürgen Roggero, Paola |
author_facet | Piemontese, Pasqua Giannì, Maria L. Braegger, Christian P. Chirico, Gaetano Grüber, Christoph Riedler, Josef Arslanoglu, Sertac van Stuijvenberg, Margriet Boehm, Günther Jelinek, Jürgen Roggero, Paola |
author_sort | Piemontese, Pasqua |
collection | PubMed |
description | BACKGROUND: the addition of oligosaccharides to infant formula has been shown to mimic some of the beneficial effects of human milk. The aim of the study was to assess the tolerance and safety of a formula containing an innovative mixture of oligosaccharides in early infancy. METHODOLOGY/PRINCIPAL FINDINGS: this study was performed as a multi-center, randomized, double-blind, placebo-controlled trial including healthy term infants. Infants were recruited before the age of 8 weeks, either having started with formula feeding or being fully breast-fed (breastfeeding group). Formula-fed infants were randomized to feeding with a regular formula containing a mixture of neutral oligosaccharides and pectin-derived acidic oligosaccharides (prebiotic formula group) or regular formula without oligosaccharides (control formula group). Growth, tolerance and adverse events were assessed at 8, 16, 24 and 52 weeks of age. The prebiotic and control groups showed similar mean weight, length and head circumference, skin fold thicknesses, arm circumference gains and stool frequency at each study point. As far as the anthropometric parameters are concerned, the prebiotic group and the control group did not attain the values shown by the breastfeeding group at any study point. The skin fold thicknesses assessed in the breastfeeding group at 8 weeks were strikingly larger than those in formula fed infants, whereas at 52 weeks were strikingly smaller. The stool consistency in the prebiotic group was softer than in the control group at 8, 16 and 24 weeks (p<0.001) and closer to that of the breastfeeding group. There was no difference in the incidence of adverse events between the two formula groups. CONCLUSIONS: our findings demonstrate the tolerability and the long term safety of a formula containing an innovative mixture of oligosaccharides in a large cohort of healthy infants. TRIAL REGISTRATION: drks-neu.uniklinik-freiburg.de DRKS 00000201 |
format | Online Article Text |
id | pubmed-3227609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32276092011-12-02 Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial Piemontese, Pasqua Giannì, Maria L. Braegger, Christian P. Chirico, Gaetano Grüber, Christoph Riedler, Josef Arslanoglu, Sertac van Stuijvenberg, Margriet Boehm, Günther Jelinek, Jürgen Roggero, Paola PLoS One Research Article BACKGROUND: the addition of oligosaccharides to infant formula has been shown to mimic some of the beneficial effects of human milk. The aim of the study was to assess the tolerance and safety of a formula containing an innovative mixture of oligosaccharides in early infancy. METHODOLOGY/PRINCIPAL FINDINGS: this study was performed as a multi-center, randomized, double-blind, placebo-controlled trial including healthy term infants. Infants were recruited before the age of 8 weeks, either having started with formula feeding or being fully breast-fed (breastfeeding group). Formula-fed infants were randomized to feeding with a regular formula containing a mixture of neutral oligosaccharides and pectin-derived acidic oligosaccharides (prebiotic formula group) or regular formula without oligosaccharides (control formula group). Growth, tolerance and adverse events were assessed at 8, 16, 24 and 52 weeks of age. The prebiotic and control groups showed similar mean weight, length and head circumference, skin fold thicknesses, arm circumference gains and stool frequency at each study point. As far as the anthropometric parameters are concerned, the prebiotic group and the control group did not attain the values shown by the breastfeeding group at any study point. The skin fold thicknesses assessed in the breastfeeding group at 8 weeks were strikingly larger than those in formula fed infants, whereas at 52 weeks were strikingly smaller. The stool consistency in the prebiotic group was softer than in the control group at 8, 16 and 24 weeks (p<0.001) and closer to that of the breastfeeding group. There was no difference in the incidence of adverse events between the two formula groups. CONCLUSIONS: our findings demonstrate the tolerability and the long term safety of a formula containing an innovative mixture of oligosaccharides in a large cohort of healthy infants. TRIAL REGISTRATION: drks-neu.uniklinik-freiburg.de DRKS 00000201 Public Library of Science 2011-11-30 /pmc/articles/PMC3227609/ /pubmed/22140499 http://dx.doi.org/10.1371/journal.pone.0028010 Text en Piemontese et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Piemontese, Pasqua Giannì, Maria L. Braegger, Christian P. Chirico, Gaetano Grüber, Christoph Riedler, Josef Arslanoglu, Sertac van Stuijvenberg, Margriet Boehm, Günther Jelinek, Jürgen Roggero, Paola Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial |
title | Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial |
title_full | Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial |
title_fullStr | Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial |
title_full_unstemmed | Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial |
title_short | Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial |
title_sort | tolerance and safety evaluation in a large cohort of healthy infants fed an innovative prebiotic formula: a randomized controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227609/ https://www.ncbi.nlm.nih.gov/pubmed/22140499 http://dx.doi.org/10.1371/journal.pone.0028010 |
work_keys_str_mv | AT piemontesepasqua toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial AT giannimarial toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial AT braeggerchristianp toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial AT chiricogaetano toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial AT gruberchristoph toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial AT riedlerjosef toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial AT arslanoglusertac toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial AT vanstuijvenbergmargriet toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial AT boehmgunther toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial AT jelinekjurgen toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial AT roggeropaola toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial AT toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial |